China Mycoplasma Testing Market Size & Outlook, 2023-2030
China mycoplasma testing market, 2018-2030 (US$M)
Related Markets
China mycoplasma testing market highlights
- The China mycoplasma testing market generated a revenue of USD 42.1 million in 2023 and is expected to reach USD 115.5 million by 2030.
- The China market is expected to grow at a CAGR of 15.5% from 2024 to 2030.
- In terms of segment, kits & reagents was the largest revenue generating product in 2023.
- Services is the most lucrative product segment registering the fastest growth during the forecast period.
Mycoplasma testing market data book summary
| Market revenue in 2023 | USD 42.1 million |
| Market revenue in 2030 | USD 115.5 million |
| Growth rate | 15.5% (CAGR from 2023 to 2030) |
| Largest segment | Kits & reagents |
| Fastest growing segment | Services |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments, Kits & Reagents, Services |
| Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
Other key industry trends
- In terms of revenue, China accounted for 4.5% of the global mycoplasma testing market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan mycoplasma testing market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 96.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Mycoplasma Testing Market Scope
Mycoplasma Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China mycoplasma testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 54.39% in 2023. Horizon Databook has segmented the China mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
The mycoplasma testing market in China is saturated, despite the low cost of production drives global investments in the country for manufacturing. For instance, in December 2021, Fujifilm announced building a new center for bioprocessing media in China. This center was aiming to provide media for biotherapeutics development, advanced therapies, & vaccines. In addition, in October 2023, Eminence Biotechnology started a GMP-grade manufacturing facility of cell culture media in Suzhou.
Furthermore, in July 2024, Merck initiated a GMP-grade cell culture media manufacturing facility in China. With an investment of over USD 6 million, the facility was expected to support local biopharma manufacturing. Moreover, China is a pioneer in stem cell research, which is projected to drive the demand for mycoplasma testing.
The presence of global players, such as Thermo Fisher Scientific, Inc. & Merck KGaA, and local suppliers aids in meeting the diverse needs of R&D in the biopharmaceutical industry in the country.
Reasons to subscribe to China mycoplasma testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China mycoplasma testing market databook
-
Our clientele includes a mix of mycoplasma testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into China mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China mycoplasma testing market size, by product, 2018-2030 (US$M)
China Mycoplasma Testing Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
